U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07616037) titled 'Efficacy of a GLP-1/FGF21 Dual Agonist for Treating PCOS' on May 04.
Brief Summary: Polycystic ovary syndrome (PCOS) is the most common reproductive endocrine and metabolic disorder among women of reproductive age. It is characterized by oligo-ovulation or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology. In addition, PCOS is frequently accompanied by multiple metabolic abnormalities, including insulin resistance, obesity, impaired glucose tolerance, and dyslipidemia. Clinical studies have demonstrated that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in women with PC...